Q2 FY27 consolidated: revenue INR 8,739m vs 7,306m year-ago; profit after tax INR 1,939m vs 1,522m.
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.9 pts more than Nifty Smallcap 250 and 4.2 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the consolidated quarter ended 30 September 2026: revenue was INR 8,739m versus INR 7,306m year ago; profit after tax was INR 1,939m versus INR 1,522m. Revenue rose 19.6 percent and profit after tax rose 27.4 percent; EBITDA margin widened from 30.7 to 32.1 percent. Also: second interim dividend of INR 5 per share, record date 11 November; up to INR 49.5 crore more Dubai investment; independent director appointed pending shareholder vote.
Positive: higher profit, a wider EBITDA margin and the dividend may support the stock, though the Dubai investment adds some execution risk.
The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.